The abstract is read at the publisher; the summary is JClub's.
A quinazolinone lead allosterically inhibits human mitochondrial ClpP with nanomolar potency by binding a distal hydrophobic pocket ~30 Å from active sites and misaligning the catalytic triad.
- Why it matters: ClpP supports mitochondrial proteostasis and is overexpressed in cancers like AML, but inhibitor development has been blocked by paradoxical activation when targeting the orthosteric site.
- What they did: Using cryo-EM and H/D exchange mass spectrometry, the study shows sub-stoichiometric binding to a distal pocket, disruption of a conserved inter-subunit cluster, and a conformational shift that inactivates ClpP.
- The result: In a xenograft mouse leukemia model, short-term oral dosing with the lead compound significantly reduced tumor burden, supporting a mechanistically distinct inhibition strategy via a regulatory hotspot.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.